Whitman-Walker Health and George Washington University’s Milken Institute School of Public Health are scheduled to host a Sept. 29 forum on the pros and cons of the controversial use of the HIV drug Truvada as a daily HIV prevention pill.
Among those scheduled to speak at the forum are Dr. Richard Elion, Whitman-Walker’s director of research, who supports the use of Truvada as an HIV prevention medication, and Michael Weinstein, president of the AIDS Healthcare Foundation.
Weinstein has spoken out against the use of Truvada as a “pre-exposure prophylaxis” drug, citing studies showing that large numbers of people didn’t adhere to the daily dose requirement, subjecting them to the risk of infection that he says could better be prevented by condom use.
Elion has said “non-adherence” to the drug is lower than critics claim and that Truvada has the potential for significantly lowering the HIV infection rate among people in high-risk groups, especially men who have sex with men.
Others scheduled to speak at the forum are Dazon Dixon Diallo, founder and CEO of the Atlanta-based SisterLove, Inc., a group that advocates for AIDS-related services for women; and Christopher Chauncey Watson, clinical research site director for GWU’s Milken Institute School of Public Health.
The event is scheduled to take place at the Institute’s first floor auditorium at 950 New Hampshire Ave., N.W. on Sept. 29 from 6:30-8:30 p.m. Go here to RSVP.